GCG and type 2 diabetes mellitus: In particular, we have demonstrated in healthy older adults that intravenous GLP-1 reduces the SMA blood flow response to intraduodenal glucose [36] and that the ‘short-acting’ GLP-1 agonist, lixisenatide, prevents the fall in systolic BP and reduces the rise in SMA flow following a 75 g oral glucose load in healthy older subjects and T2DM patients [37].